Cancer Immunotherapies UAE: Regulatory and Access Insights 2025
This article provides essential insights into the regulatory landscape and access to cancer immunotherapies in the UAE, focusing on key drugs and future trends.
Key Takeaways
The United Arab Emirates is advancing its position as a regional leader in cancer immunotherapy adoption, with the launch of its first tumor-infiltrating lymphocyte (TIL) therapy program in 2025. This development complements the region's existing portfolio of checkpoint inhibitors and CAR-T cell therapies, supported by key institutions including Abu Dhabi Stem Cells Center and Cleveland Clinic Abu Dhabi. Why it matters: The UAE's pioneering approach to immunotherapy access reflects growing regional investment in advanced oncology treatments and positions the country as a model for immunotherapy implementation across the Middle East and North Africa region.
Cancer Immunotherapy Landscape in the UAE
The UAE healthcare system has embraced a comprehensive approach to cancer immunotherapy, incorporating three primary modalities: checkpoint inhibitors, CAR-T cell therapies, and the newly launched tumor-infiltrating lymphocyte (TIL) therapies. Checkpoint inhibitors, including agents targeting programmed death-1 (PD-1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) pathways, have been integrated into standard oncology protocols for various malignancies. CAR-T cell therapies, which involve engineering patient-derived T cells to recognize and eliminate cancer cells expressing specific antigens, represent a more specialized immunotherapy modality previously limited to hematologic malignancies but increasingly explored in solid tumors.
The introduction of TIL therapy represents a notable expansion of the UAE's immunotherapy arsenal. TIL therapies involve isolating tumor-infiltrating lymphocytes from patient tumors, expanding them ex vivo, and reinfusing them to target residual disease. The UAE's first TIL program, launched in 2025, focuses on solid tumors including breast cancer, non-small cell lung cancer, and melanoma—indications where TIL therapy has demonstrated clinical activity in international trials.
Regulatory and Institutional Framework
The adoption of advanced cancer immunotherapies in the UAE operates within a regulatory framework overseen by the Ministry of Health (MOH) and the Department of Health Abu Dhabi (DOH). While specific regulatory pathways for immunotherapies have not been formally detailed, the UAE's regulatory bodies align with international standards established by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), and coordinate with the GCC Drug Registration Office (GCC-DR) to harmonize approvals across the Gulf Cooperation Council region.
Abu Dhabi Stem Cells Center and Cleveland Clinic Abu Dhabi serve as anchor institutions for immunotherapy implementation. ADSCC brings specialized expertise in cell therapy manufacturing and regenerative medicine approaches applicable to CAR-T and TIL production. CCAD, as a tertiary care center, provides clinical infrastructure, multidisciplinary oncology teams, and patient management capabilities essential for delivering complex immunotherapies. These institutions have established the operational capacity—including Good Manufacturing Practice (GMP) facilities, clinical trial infrastructure, and specialized nursing and pharmacy support—required for safe and effective immunotherapy delivery.
Clinical Implementation: Solid Tumor Applications
The UAE's first TIL therapy program targets three primary solid tumor indications: breast cancer, lung cancer, and melanoma. These indications were selected based on clinical evidence from international studies demonstrating TIL activity and the prevalence of these malignancies in the UAE population.
Breast Cancer: TIL therapy is being evaluated in hormone receptor-positive and triple-negative breast cancer subtypes. The approach complements existing checkpoint inhibitor and HER2-targeted therapies, offering an alternative for patients with limited response to conventional immunotherapy.
Lung Cancer: Non-small cell lung cancer (NSCLC) represents a key indication, particularly for patients with PD-L1-positive tumors or those progressing on checkpoint inhibitor monotherapy. TIL therapy's potential to overcome resistance mechanisms in NSCLC makes it a strategically important addition to the UAE's oncology treatment portfolio.
Melanoma: Melanoma, historically responsive to immunotherapy, remains a priority indication. The integration of TIL therapy with checkpoint inhibitors or other immunomodulatory approaches may enhance response rates and durability in this patient population.
Reimbursement and Market Access Challenges
The introduction of advanced immunotherapies in the UAE presents both opportunities and challenges related to reimbursement and patient access. CAR-T cell therapies and TIL therapies are among the most expensive oncology treatments available, with costs often exceeding USD 300,000–500,000 per patient in global markets. Compared with conventional chemotherapy and even first-generation checkpoint inhibitors, these therapies require substantial healthcare system investment.
The UAE's healthcare system comprises both government-funded and private insurance mechanisms. Government healthcare facilities, including those operated by DOH Abu Dhabi and the Ministry of Health, have demonstrated willingness to invest in novel therapies when clinical evidence supports efficacy. However, reimbursement decisions require rigorous health economic assessments, budget impact analyses, and cost-effectiveness evaluations to ensure sustainable access.
Insurance coverage policies for immunotherapies vary across private payers in the UAE. Some insurers have established specific criteria for CAR-T and TIL therapy coverage, including disease stage, prior treatment lines, and performance status thresholds. These policies aim to optimize resource allocation while ensuring patients with the highest likelihood of benefit receive access to these treatments.
Barriers to equitable access include the geographic concentration of advanced immunotherapy programs in Abu Dhabi, potential disparities in insurance coverage across different payer segments, and the need for patient education regarding novel treatment modalities. Strategies to address these barriers include expanding institutional capacity beyond Abu Dhabi to other emirates, establishing clear reimbursement pathways through collaboration with payers, and implementing patient support programs.
Regulatory Harmonization and Global Alignment
The UAE's immunotherapy regulatory framework operates within a broader context of regional and global alignment. While the MOH and DOH make final approval decisions for therapies marketed in the UAE, regulatory pathways are informed by FDA and EMA assessments. This approach leverages international regulatory expertise while maintaining sovereignty over local approval decisions.
The GCC Drug Registration Office coordinates drug approvals across GCC member states, including the UAE, Saudi Arabia, Kuwait, Qatar, Bahrain, and Oman. This coordination mechanism facilitates harmonized approval timelines for new oncology drugs, reducing duplicative review processes and accelerating patient access across the region.
However, regulatory harmonization challenges persist. Differences in clinical trial conduct standards, manufacturing requirements for cell therapies, and post-market surveillance capabilities across GCC countries may delay approvals or create inconsistencies in product availability. The UAE's investment in institutional capacity at ADSCC and CCAD partially addresses these challenges by establishing local manufacturing and clinical expertise, reducing dependence on imported cell therapy products.
Future Outlook: Expanding Immunotherapy Access and Innovation
The UAE's immunotherapy landscape is poised for continued expansion. What to watch next: regulatory pathways for combination immunotherapies (e.g., TIL plus checkpoint inhibitors), expansion of TIL programs to additional indications such as ovarian and gastric cancers, and potential establishment of CAR-T manufacturing capacity within the UAE to reduce costs and improve access.
Emerging trends include personalized immunotherapy approaches utilizing tumor genomic profiling to predict treatment response, combination regimens integrating multiple immunotherapy modalities, and biomarker-driven patient selection to optimize outcomes and minimize toxicity. Real-world evidence generation through institutional registries and prospective data collection will be critical for understanding immunotherapy effectiveness, safety, and cost-effectiveness in the UAE population.
Strategic recommendations for stakeholders include: (1) continued investment in institutional capacity and workforce training to support immunotherapy delivery; (2) establishment of clear regulatory pathways and reimbursement frameworks to facilitate timely access; (3) participation in international clinical trials to generate evidence relevant to UAE and MEA populations; (4) development of patient and physician education programs to support informed decision-making; and (5) collaboration with regional and international centers to share best practices and optimize outcomes.
Frequently Asked Questions
What is tumor-infiltrating lymphocyte (TIL) therapy and how does it differ from CAR-T cell therapy?
TIL therapy involves isolating T cells that have naturally infiltrated a patient's tumor, expanding these cells in the laboratory, and reinfusing them to target residual disease. Unlike CAR-T cell therapy, which genetically engineers T cells to express chimeric antigen receptors targeting specific tumor antigens, TIL therapy uses cells that already recognize tumor-associated antigens. TIL therapy can be applied to solid tumors and does not require genetic modification, potentially reducing manufacturing complexity and cost compared with CAR-T approaches.
Which patient populations are eligible for TIL therapy in the UAE?
The UAE's first TIL therapy program targets patients with solid tumors including breast cancer, non-small cell lung cancer, and melanoma. Eligibility criteria typically include adequate tumor tissue for TIL isolation, adequate performance status (usually Eastern Cooperative Oncology Group score 0–1), and prior treatment history. Specific inclusion and exclusion criteria are determined by treating institutions (ADSCC and CCAD) based on international guidelines and institutional protocols.
How is reimbursement determined for CAR-T and TIL therapies in the UAE?
Reimbursement decisions are made by government healthcare facilities and private insurance payers based on clinical efficacy, safety data, cost-effectiveness assessments, and budget impact analyses. Government-funded healthcare facilities may prioritize therapies with strong clinical evidence and alignment with international guidelines. Private insurers typically establish specific coverage criteria, including disease stage, prior treatment lines, and performance status thresholds. Patients should verify coverage with their specific insurance provider or healthcare facility prior to treatment initiation.
What is the role of Abu Dhabi Stem Cells Center and Cleveland Clinic Abu Dhabi in immunotherapy delivery?
ADSCC provides specialized expertise in cell therapy manufacturing, including GMP-compliant production of CAR-T and TIL cells. CCAD offers clinical oncology services, patient management, and multidisciplinary care coordination. Together, these institutions provide the infrastructure, expertise, and clinical capacity necessary for safe and effective delivery of advanced immunotherapies in the UAE.
Are there plans to expand immunotherapy programs to other emirates beyond Abu Dhabi?
While current TIL and CAR-T programs are concentrated in Abu Dhabi institutions, the UAE's broader healthcare strategy includes expanding specialized oncology services across the country. Future expansion of immunotherapy programs to other emirates will depend on institutional capacity development, regulatory support, and reimbursement frameworks. Patients in other emirates may access immunotherapies through referral arrangements with Abu Dhabi-based centers.
References
- Abu Dhabi Stem Cells Center and Cleveland Clinic Abu Dhabi. Institutional reports on tumor-infiltrating lymphocyte therapy program launch and cancer immunotherapy adoption in the UAE, 2025.
